Related Experiment Video
Updated: Aug 7, 2026

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
The frequency of atrioventricular block during adenosine stress testing in young, middle-aged, young-old, and old-old
G S Alkoutami1, W C Reeves, A Movahed
1Section of Cardiology, Department of Medicine, East Carolina University School of Medicine, Greenville, NC 27858, USA.
Abstract:
The frequency of atrioventricular (AV) block was evaluated in 600 consecutive patients of different age groups referred for pharmacologic stress testing. Adenosine was infused at 140 mg/kg/min for a total of 6 minutes in conjunction with radionuclide myocardial perfusion imaging. Seventy-five patients (12.5%) were young adults (< 49 years old), 214 (35.6%) were middle-aged (50-65 years), 195 (32.6%) were young-old (66-75 years), and 116 patients (19.3%) were old-old (over 75 years). The frequencies of first-degree AV block in young adults, middle-aged, young-old, old-old, and all ages were 14.6%, 9.3%, 14.3%, 17.24%, and 13.16%, respectively. The frequencies of second-degree AV block were 14.65%, 7.0%, 8.7%, 15.5%, and 10.1%, respectively. The frequencies of third-degree AV block were 2.66%, 2.33%, 1.0%, 2.58%, and 2.0%, respectively. Comparison of the incidence of the three types of AV block for each age group vs. all patients showed no statistically significant difference (p > 0.08). All types of AV block were of short duration, were well tolerated, and did not require discontinuation of the adenosine infusion or specific treatment. This study confirms the safety of adenosine stress testing in all age groups for evaluation of coronary artery disease and risk assessment.
Related Concept Videos
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Heart Failure Drugs: β-Blockers
Dysrhythmias IV: Characteristics of Bradyarrhythmias

